CA2295029A1 - Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo - Google Patents

Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo Download PDF

Info

Publication number
CA2295029A1
CA2295029A1 CA002295029A CA2295029A CA2295029A1 CA 2295029 A1 CA2295029 A1 CA 2295029A1 CA 002295029 A CA002295029 A CA 002295029A CA 2295029 A CA2295029 A CA 2295029A CA 2295029 A1 CA2295029 A1 CA 2295029A1
Authority
CA
Canada
Prior art keywords
pulses
electrode
tissue
volts
electrotransfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002295029A
Other languages
English (en)
French (fr)
Inventor
Daniel Scherman
Bertrand Schwartz
Lluis Mir
Michel Bureau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Aventis Pharma SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9708233A external-priority patent/FR2765242B1/fr
Priority claimed from FR9708232A external-priority patent/FR2765241B1/fr
Application filed by Individual filed Critical Individual
Publication of CA2295029A1 publication Critical patent/CA2295029A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002295029A 1997-06-30 1998-06-30 Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo Abandoned CA2295029A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
FR97/08233 1997-06-30
FR9708233A FR2765242B1 (fr) 1997-06-30 1997-06-30 Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
FR97/08232 1997-06-30
FR9708232A FR2765241B1 (fr) 1997-06-30 1997-06-30 Amelioration du transfert d'acide nucleique dans les cellules d'organismes eucaryotes pluricellulaires et combinaison permettant la mise en oeuvre du procede
US6748797P 1997-12-01 1997-12-01
US6748897P 1997-12-01 1997-12-01
US60/067,488 1997-12-01
US60/067,487 1997-12-01
US8385898P 1998-05-01 1998-05-01
US60/083,858 1998-05-01
PCT/EP1998/003976 WO1999001175A1 (en) 1997-06-30 1998-06-30 Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo

Publications (1)

Publication Number Publication Date
CA2295029A1 true CA2295029A1 (en) 1999-01-14

Family

ID=27515625

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002295029A Abandoned CA2295029A1 (en) 1997-06-30 1998-06-30 Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo

Country Status (11)

Country Link
EP (1) EP0993318A1 (no)
JP (1) JP2002515816A (no)
KR (1) KR20010014298A (no)
CN (1) CN1261812A (no)
AU (1) AU8730798A (no)
BR (1) BR9810500A (no)
CA (1) CA2295029A1 (no)
IL (1) IL133709A0 (no)
NO (1) NO996540L (no)
PL (1) PL337617A1 (no)
WO (1) WO1999001175A1 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2753379B1 (fr) 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
CA2361601A1 (en) * 1999-02-08 2000-08-10 Cheryl Goldbeck Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
WO2001068131A1 (en) 2000-03-13 2001-09-20 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with cd99/hec2
JP2003531149A (ja) 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
JP2004532654A (ja) 2000-05-22 2004-10-28 マーク・アンド・カンパニー・インコーポレイテッド 薬剤投与システム性能評価システム及び方法
CN100422210C (zh) 2000-12-28 2008-10-01 Wyeth公司 来自肺炎链球菌的重组防护蛋白质
JP2005508134A (ja) 2001-03-02 2005-03-31 ザ ロックフェラー ユニヴァーシティ 天然アレルゲンの免疫原性を保持する、アレルゲン性が低下した組み換えハイブリッドアレルゲン構築体
US20020198567A1 (en) * 2001-06-07 2002-12-26 Yona Keisari Electro-endocytotic therapy as a treatment modality of cancer
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US20050154434A1 (en) 2002-03-07 2005-07-14 Adam Simon Clinical syringe with electrical stimulation aspects
US7217796B2 (en) 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP1759714A1 (en) * 2005-09-02 2007-03-07 Bioalliance Pharma Electrotransfer of nucleic acid into tissue cells
CA2624624C (en) * 2005-10-03 2016-07-19 Novocure Limited Optimizing characteristics of an electric field to increase the field's effect on proliferating cells
JP4961137B2 (ja) * 2005-12-14 2012-06-27 久光製薬株式会社 イオントフォレーシス用デバイス
WO2008060814A2 (en) 2006-10-19 2008-05-22 Merck & Co., Inc. ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF
DK2068921T3 (da) 2006-10-19 2014-09-15 Csl Ltd Antistof-antagonister med høj affinitet af interleukin-13-receptor alpha 1
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US8246176B2 (en) 2007-03-06 2012-08-21 Sanyo Electric Co., Ltd. Projection display device having an operation section for displacing a lens
US8093043B2 (en) 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
EP2310500B1 (en) * 2008-07-18 2015-03-11 Maxcyte, Inc. Methods for optimizing electroporation
MX2011004755A (es) 2008-11-05 2011-10-10 Wyeth Llc Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta-hemolitica (bhs).
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
KR101763625B1 (ko) 2012-03-09 2017-08-01 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US9822150B2 (en) 2013-09-08 2017-11-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317380D0 (en) * 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
US5641680A (en) * 1994-11-14 1997-06-24 Zhao; Xi Gene transfer apparatus and method for using the same
WO1997007826A1 (en) * 1995-08-29 1997-03-06 Cbr Laboratories, Inc. In vivo electroporation of cells

Also Published As

Publication number Publication date
IL133709A0 (en) 2001-04-30
EP0993318A1 (en) 2000-04-19
PL337617A1 (en) 2000-08-28
NO996540D0 (no) 1999-12-29
CN1261812A (zh) 2000-08-02
BR9810500A (pt) 2000-09-05
JP2002515816A (ja) 2002-05-28
AU8730798A (en) 1999-01-25
NO996540L (no) 2000-02-03
WO1999001175A1 (en) 1999-01-14
KR20010014298A (ko) 2001-02-26

Similar Documents

Publication Publication Date Title
CA2295029A1 (en) Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
US6939862B2 (en) Method for transferring nucleic acid into striated muscles
JP4664450B2 (ja) 多細胞化真核生物細胞に核酸を導入する改良法およびその組合せ
US7054685B2 (en) Method and apparatus for reducing electroporation-mediated muscle reaction and pain response
Vicat et al. Brief report: muscle transfection by electroporation with high-voltage and short-pulse currents provides high-level and long-lasting gene expression
Heller et al. Electrically mediated delivery of plasmid DNA to the skin, using a multielectrode array
EP1171189B1 (en) Apparatus for reducing electroporation-mediated muscle reaction and pain response
Prausnitz et al. Methods for in vivo tissue electroporation using surface electrodes
MXPA99011527A (en) Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
CZ475699A3 (cs) Systém a zařízení pro in vivo přenos nukleových kyselin do tkání
MXPA99011444A (es) Metodo mejorado de transferencia de acidos nucleicos enmusculo estraido y combinaciones que permienn el uso del procedimiento
JP2005524389A (ja) 宿主組織内への核酸分子の電気的遺伝子導入の増強
AU4439102A (en) Improved method for transferring nucleic acid into the striped muscle and combination therefor
AU4576202A (en) Improvement in the transfer of nucleic acid into the cells of pluricellular eukaryotic organisms and combination allowing the method to be carried out

Legal Events

Date Code Title Description
FZDE Discontinued